Prevention Of P.P.H: Oxytocin Versus Misoprostol

Authors: Safia Maqsood Siddiqui, Jan Mohammod Shaikh, Kauser Aqil Jillani, Maqsood Ahmed Siddiqui

PEOPLES MEDICAL COLLEGE HOSPITAL, NAWABSHAH
DEPARTMENT OF ANAESTHESIOLOGY AND ICU LUMHS JAMSHORO / HYDERABAD
PEOPLES MEDICAL COLLEGE HOSPITAL, NAWABSHAH
ICU & PAIN MANAGEMENT, PEOPLES MEDICAL COLLEGE HOSPITAL, NAWABSHAH

Volume 15 | Issue 2

Published: November 12, 2026

Abstract

The aim of this study was to compare the rectally administrated misoprostol
400 microgram with oxytocin 10 units I/V for the active management of the 3rd stage of labour for the prevention of primary postpartum haemorrhage and to assess the incidence and severity of the side effects of the both drug regimens. Study Design: Quasi-experimental study. Study Period: October 2006 – September 2007. Setting: Department of Gynaecology & Obstetrics Peoples Medical College & Hospital Nawabshah. Material & Methods: This study was carried out on 200 patients, misoprostol and oxytocin was given to 100 patients each. Women of any age and parity with singleton pregnancy delivered vaginally were included while those who refuses to give consent, with established PPH and have cesarean delivery were excluded . Data was collected on maternal and labour charactertstics. Active management of the 3rd stage of labour was done by giving misoprostol or oxytocin at delivery of the anterior
shoulder of the baby and placenta was delivered by controlled cord traction and gentle
uterine massage done after delivery of the placenta. Women were observed up to one hour after the delivery and blood loss was collected in measured container. Treatment outcomes were recorded, like duration of 3rd stage, total blood loss and postpartum side effects of the drugs. Statistical analysis was performed by using chi square and student’s t-test. A p-value of < .05 was considered statistically significant. Results: No women in both groups had prolonged 3rd stage of labour. Mean 3rd stage duration of misoprostol group was 5.70 (SD = 4.25) and oxytocin group was 6.04 (SD = 4.25). Mean blood loss was greater in misoprostol group (p < 0.3). PPH developed in 36 % misoprostol group and 30 % in oxytocin group (p < 0.250). Uterine atony remained the commonest cause of PPH in both group. No patient in both groups had retained placenta. Postpartum side effects were more in the misoprostol group, 6 % had fever, 4 % had shivering, 1 % had nausea, 1 % had headache and 1 % had abdominal pain. While in oxytocin group, 7 % had fever and 2 % had shivering (p < 0.010). In both groups, primary PPH was well managed, without surgical intervention and none of the maternal death recorded. Conclusion: PPH occurred more frequently in the 400 mg rectally administrated misoprostol when compared to 10 units intravenous oxytocin although statistically not significant. Considering the safety of rectal route of misoprotal as compared to oral route administration, it just needs a dose adjustment for improving its safety.

Keywords: Misoprostol, Oxytocin, Active management, 3rd stage, Prevention, Postpartum Haemorrhage

DOI: (All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.)

Download Full Text PDF